enGene Therapeutics Inc. (ENGN) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for enGene Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Price
$1.58
+1.94% today
Market cap
$104M
Overall quality
46/100
Kronos AI 30-day
+11.2%
8 of 8 simulated paths end higher
enGene Therapeutics Inc. (ENGN) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $104M. It trades at $1.58, up 1.94% today. Its overall quality score is 46 out of 100, ranked against the whole US market. 6 analysts' average target of $2.80 implies +77.2% from today's price. Kronos AI's 30-day forecast is +11.2% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $2.80 |
| Low – high | $2.00 – $4.00 |
| Analysts | 6 |
| Upside to average | +77.2% |
Kronos AI 30-day forecast
| Expected close | $1.72 (+11.2%) |
| Likely range | +8.5% … +16.6% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 39 |
| Solvency | 58 |
| Growth | 40 |
| Overall | 46 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Biological Products (No Diagnostic Substances)
For information only, not investment advice. Prices updated: 2026-10-29.